Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research von Kipps, Emma, Tan, David S. P., Kaye, Stan B.

Volltext

Beyond chemotherapy: targeted therapies in ovarian cancer von Kaye, Stan B, Yap, Timothy A, Carden, Craig P

Volltext

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial von Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

Volltext

Ovarian cancer: strategies for overcoming resistance to chemotherapy von Agarwal, Roshan, Kaye, Stan B

Volltext

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial von Sandhu, Shahneen K, MD, Schelman, William R, MD, Wilding, George, MD, Moreno, Victor, MD, Baird, Richard D, PhD, Miranda, Susana, BSc, Hylands, Lucy, BSc, Riisnaes, Ruth, FIBMS, Forster, Martin, PhD, Omlin, Aurelius, MD, Kreischer, Nathan, MSc, Thway, Khin, MD, Gevensleben, Heidrun, MD, Sun, Linda, PhD, Loughney, John, PhD, Chatterjee, Manash, PhD, Toniatti, Carlo, PhD, Carpenter, Christopher L, MD, Iannone, Robert, MD, Kaye, Stan B, Prof, de Bono, Johann S, Prof, Wenham, Robert M

Volltext

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in... von KAYE, Stan B, LUBINSKI, Jan, SAFRA, Tamar, VERGOTE, Ignace, WICKENS, Mark, LOWE, Elizabeth S, CARMICHAEL, James, KAUFMAN, Bella, MATULONIS, Ursula, ERN ANG, Joo, GOURLEY, Charlie, KARLAN, Beth Y, AMNON, Amit, BELL-MCGUINN, Katherine M, CHEN, Lee-May, FRIEDLANDER, Michael

Volltext

Rethinking ovarian cancer: recommendations for improving outcomes von Bowtell, David D, Vaughan, Sebastian, Coward, Jermaine I, Bast, Robert C, Berchuck, Andy, Berek, Jonathan S, Brenton, James D, Coukos, George, Crum, Christopher C, Drapkin, Ronny, Etemadmoghadam, Dariush, Friedlander, Michael, Gabra, Hani, Kaye, Stan B, Lord, Chris J, Lengyel, Ernst, Levine, Douglas A, McNeish, Iain A, Menon, Usha, Mills, Gordon B, Nephew, Kenneth P, Oza, Amit M, Sood, Anil K, Stronach, Euan A, Walczak, Henning, Balkwill, Frances R

Volltext

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval von FONG, Peter C, YAP, Timothy A, A'HERN, Roger, TUTT, Andrew, ASHWORTH, Alan, STONE, John, CARMICHAEL, James, SCHELLENS, Jan H. M, DE BONO, Johann S, KAYE, Stan B, BOSS, David S, CARDEN, Craig P, MERGUI-ROELVINK, Marja, GOURLEY, Charlie, DE GREVE, Jacques, LUBINSKI, Jan, SHANLEY, Susan, MESSIOU, Christina

Volltext

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer von Attard, Gerhardt, Reid, Alison H M, A'Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B, Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S

Volltext

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven von ATTARD, Gerhardt, REID, Alison H. M, CLARK, Jeremy, COOPER, Colin S, KAYE, Stan B, DEARNALEY, David, LEE, Gloria, DE BONO, Johann S, YAP, Timothy A, RAYNAUD, Florence, DOWSETT, Mitch, SETTATREE, Sarah, BARRETT, Mary, PARKER, Christopher, MARTINS, Vanessa, FOLKERD, Elizabeth

Volltext

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma von RATAIN, Mark J, EISEN, Tim, ROWINSKY, Eric, ABBRUZZESE, James L, CHENGHUA XIA, SIMANTOV, Ronit, SCHWARTZ, Brian, O'DWYER, Peter J, STADLER, Walter M, FLAHERTY, Keith T, KAYE, Stan B, ROSNER, Gary L, GORE, Martin, DESAI, Apurva A, PATNAIK, Amita, XIONG, Henry Q

Volltext

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers von Perkins, Geraldine, Yap, Timothy A, Pope, Lorna, Cassidy, Amy M, Dukes, Juliet P, Riisnaes, Ruth, Massard, Christophe, Cassier, Philippe A, Miranda, Susana, Clark, Jeremy, Denholm, Katie A, Thway, Khin, Gonzalez De Castro, David, Attard, Gerhardt, Molife, L Rhoda, Kaye, Stan B, Banerji, Udai, de Bono, Johann S

Volltext

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies von YAP, Timothy A, OLMOS, David, COLLINS, David, DESOUZA, Nandita M, LEACH, Martin O, SAVAGE, Ronald E, WAGHORNE, Carol, FENG CHAI, GARMEY, Edward, SCHWARTZ, Brian, KAYE, Stan B, DE BONO, Johann S, BRUNETTO, Andre T, TUNARIU, Nina, BARRIUSO, Jorge, RIISNAES, Ruth, POPE, Lorna, CLARK, Jeremy, FUTREAL, Andrew, GERMUSKA, Michael

Volltext

Reversal of drug resistance in ovarian cancer: where do we go from here? von Kaye, Stan B

Volltext

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey von Paoletti, Xavier, Le Tourneau, Christophe, Verweij, Jaap, Siu, Lillian L, Seymour, Lesley, Postel-Vinay, Sophie, Collette, Laurence, Rizzo, Elisa, Ivy, Percy, Olmos, David, Massard, Christophe, Lacombe, Denis, Kaye, Stan B, Soria, Jean-Charles

Volltext

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer von Hoppe, Michal M, Jaynes, Patrick, Wardyn, Joanna D, Upadhyayula, Sai Srinivas, Tan, Tuan Zea, Lie, Stefanus, Lim, Diana G Z, Pang, Brendan N K, Lim, Sherlly, P S Yeong, Joe, Karnezis, Anthony, Chiu, Derek S, Leung, Samuel, Huntsman, David G, Sedukhina, Anna S, Sato, Ko, Topp, Monique D, Scott, Clare L, Choi, Hyungwon, Patel, Naina R, Brown, Robert, Kaye, Stan B, Pitt, Jason J, Tan, David S P, Jeyasekharan, Anand D

Volltext

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial von CRAWFORD, Simon C, VASEY, Paul A, PAUL, Jim, HAY, Andrea, DAVIS, Jo A, KAYE, Stan B

Volltext

PARP inhibitors: the race is on von Brown, Jessica S, Kaye, Stan B, Yap, Timothy A

Volltext

Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors von OLMOS, David, A'HERN, Roger P, SCHELLENS, Jan H, DEL CONTE, Gianluca, BRUNETTO, Andre T, JEFFRY EVANS, T. R, WILSON, Richard, GALLERANI, Elisa, PLUMMER, Ruth, TABERNERO, Josep, SORIA, Jean-Charles, KAYE, Stan B, MARSONI, Silvia, MORALES, Rafael, GOMEZ-ROCA, Carlos, VERWEIJ, Jaap, VOEST, Emile E, SCHÖFFSKI, Patrick, JOO ERN ANG, PENEL, Nicolas

Volltext

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype von GOURLEY, Charlie, MICHIE, Caroline O, HAYWARD, Richard L, MITCHELL, Paul, RYE, Tzyvia, SCHELLENS, Jan H. M, LUBINSKI, Jan, CARMICHAEL, James, KAYE, Stan B, MACKEAN, Melanie, FERGUSON, Michelle, ROXBURGH, Patricia, YAP, TimothyA, HARDEN, Sharon, PAUL, Jim, RAGUPATHY, Kalpana, TODD, Radha, PETTY, Russell, REED, Nick

Volltext